ArticleClinical rheumatology2021
Interleukin-29 and interleukin-28A induce migration of neutrophils in rheumatoid arthritis.
Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years.Frontiers in medicine · 2024Review
- Are comorbidities associated with the cytokine/chemokine profile of persistent apical periodontitis?Clinical oral investigations · 2023Article
- Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesType III Interferons, interleukin (IL)-29 and IL-28A, have been implicated in the inflammatory response of rheumatoid arthritis (RA). Increasing evidence suggests an important role of neutrophils in the pathogenesis of RA. However, the underlying mechanism remains unclear. Therefore, we investigated the expression of the receptor of these type III interferons, IL-28R1, on the neutrophils of RA patients, and further explored the roles of IL-29 and IL-28A on neutrophil activity.
methodsNeutrophils were extracted from peripheral blood of patients who met the diagnostic criteria for RA and healthy controls. The serum levels of IL-29 and IL-28A in RA patients and healthy controls were examined by enzyme-linked immunoassay, and the expression of IL-28R1 on neutrophils was determined by flow cytometry. A transwell assay was performed to determine the chemotactic ability of IL-29 and IL-28A to neutrophils in RA patients.
resultsThe serum IL-29 but not IL-28A levels were significantly elevated in RA patients, and neither was correlated with RA disease activity. IL-28R1 levels on neutrophils were significantly (p < 0.001) elevated in patients with RA (51.85% (36.10%, 67.03%)) compared with those of healthy controls (4.13% (3.54%, 7.96%)), and IL-29 and IL-28A had a significant chemotactic effect on neutrophils from the peripheral blood of RA patients.
conclusionIL-29 and IL-28A play an important role in regulating neutrophils which participate in the pathogenesis of RA. Therefore, inhibiting IL-29 and IL-28A may be a new therapeutic strategy for RA. Key points • The IL-28R1 levels were increased in neutrophils of RA patients, suggesting its potentially important role in the pathogenesis of RA. • IL-29 and IL-28A induce the migration of neutrophils that participate in the development of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.